Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) and R...

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Regeneron (REGN)

U.S. stocks ended the week lower as pressure from rates and commodities weighed on risk appetite. The Dow Jones Industrial Average (DJIA) fell 0.36...

The Week That Was, The Week Ahead: Macro and Markets, Feb. 1

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview – Bristol-Myers Squibb (BMY) is running a P...

Bristol-Myers Squibb Advances Repotrectinib Interaction Study: What Investors Should Know

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb is running a 12‑month...

Bristol-Myers Squibb’s KarXT Safety Study: What Long-Term Urological Data Could Mean for BMY Investors

There’s plenty of stock market stories worth reading on Tuesday following the long weekend.


Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Bristol Myers Squibb ($BMY) and Microsoft ($MSFT) have launched a new initiative to tackle lung cancer using artificial intelligence. The partnersh...

Bristol Myers and Microsoft Partner to Accelerate AI Lung Cancer Detection

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview This Bristol-Myers Squibb (BMY) trial, titl...

Bristol-Myers Squibb Advances Liver Cancer Combo as Key Trial Reaches Completion

An announcement from Bristol-Myers Squibb ( ($BMY) ) is now available. On January 12, 2026, Bristol Myers Squibb used its appearance at the 44th An...

Bristol Myers Squibb Showcases Growth Strategy at JPM Conference

Tempus AI’s ($TEM) preliminary results show its total contract value (TCV) surpassed $1.1 billion, marking the highest level in its history. The up...

Tempus AI (TEM) Tops $1.1B in Total Contract Value as Pharma Demand for AI Tools Surges

Bristol-Myers Squibb Company ($BMY), Biontech Se Sponsored Adr ($BNTX) announced an update on their ongoing clinical study. Study Overview: BioNTec...

BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview: Bristol Myers Squibb (BMY) has launched a ...

Bristol Myers Squibb Adds New Immunotherapy Combo Bet in Small Cell Lung Cancer

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb is launching a Phase ...

Bristol-Myers Squibb Targets Autism Irritability With New Phase 3 Trial, Expanding Its Neuroscience Reach

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study OverviewBristol-Myers Squibb is running an early-sta...

Bristol-Myers Squibb Quietly Expands Pipeline With New First-in-Human Study of BMS-986521

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview Bristol-Myers Squibb (BMY) is backing a com...

Bristol-Myers Squibb’s Real-World Lung Cancer Study Adds Support for Nivolumab Growth Story

Piper Sandler analyst David Amsellem reiterated a Buy rating on Bristol-Myers Squibb today and set a price target of $62.00. Amsellem covers the He...

Piper Sandler Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview Bristol-Myers Squibb is launching a late-st...

Bristol-Myers Squibb Advances Phase 3 Autism Irritability Program With KarXT Combo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and Bio...

Current Quarter	$1.25	Next Quarter	$1.51
Current Year	$6.16	Next Year	$6.08
QoQ Growth	+20.8%	YoY Growth	-1.3%
3Y EPS CAGR	-50.4%	Target Price	$57.25
Consensus	Buy	Upside	+1.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMY	$56.26	+0.65%	7.23M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMY	$56.26	+0.7%	7.23M
3
4
5
6

BMY

BMY

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Bristol-Myers Squibb Company Data in Excel

Get Bristol-Myers Squibb Company Data in Excel